

What is claimed is:

1. A pharmaceutical composition comprising about 5 to about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.055 to 0.56 mg naltrexone or pharmaceutically acceptable salt thereof, said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof in a ratio of from 0.011:1 to 0.028:1.
2. The pharmaceutical composition of claim 1 comprising about 5 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.055 mg to 0.14 mg of naltrexone or pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition of claim 1 comprising about 7.5 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.0825 mg to 0.21 mg of naltrexone or pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 1 comprising about 10 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.11 mg to 0.28 mg of naltrexone or pharmaceutically acceptable salt thereof.
5. The pharmaceutical composition of claim 1 comprising about 15 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.165 mg to 0.42 mg of naltrexone or pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition of claim 1 comprising about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and from 0.22 mg to 0.56 mg of naltrexone or pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 1 comprising about 5 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.0625 mg of naltrexone or pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of claim 1 comprising about 7.5 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.09375 mg of naltrexone or pharmaceutically acceptable salt thereof.
9. The pharmaceutical composition of claim 1 comprising about 10 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.125 mg of naltrexone or pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition of claim 1 comprising about 15 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.1875 mg of naltrexone or pharmaceutically acceptable salt thereof.
11. The pharmaceutical composition of claim 1 comprising about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.25 mg of naltrexone or pharmaceutically acceptable salt thereof.
12. The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of the hydrocodone or pharmaceutically acceptable salt thereof.
13. The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of the naltrexone or pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 1 further comprising a sustained release excipient which provides a sustained release of the hydrocodone or pharmaceutically acceptable salt thereof and the naltrexone or pharmaceutically acceptable salt thereof.
15. The pharmaceutical composition of claim 12 and 14 wherein the dosage form provides effective pain relief for at least 12 hours after steady state oral administration to human patients.

16. The pharmaceutical composition of claim 12 and 14 wherein the dosage form provides effective pain relief for at least 24 hours after steady state oral administration to human patients.
17. The pharmaceutical composition of claim 14 wherein the hydrocodone or pharmaceutically acceptable salt thereof and the naltrexone or pharmaceutically acceptable salt thereof are substantially interdispersed in said sustained release excipient.
18. The pharmaceutical composition of claims 1-11 wherein said hydrocodone is in the form of the bitartrate salt.
19. The pharmaceutical composition of claims 1-11 wherein said naltrexone is in the form of the hydrochloride salt.
20. The pharmaceutical composition of claims 1-19 further comprising a non-steroidal anti-inflammatory drug selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acetaminophen, fentanyl, clidazepam, oxycodone, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolafenamic acid, diflunisal, flufenisal, piroxicam, sudoxicam, isoxicam, pharmaceutically acceptable salts thereof and mixtures thereof
21. A method of treating pain in a human patient comprising orally administering a pharmaceutical composition according to claims 1-20.
22. A method of preparing a pharmaceutical composition comprising combining about 5 to about 20 mg hydrocodone or pharmaceutically acceptable salt thereof and 0.055 to 0.56 mg naltrexone or pharmaceutically acceptable salt thereof into an oral dosage form, said naltrexone or pharmaceutically acceptable salt thereof and said hydrocodone or pharmaceutically acceptable salt thereof in a ratio of from 0.011:1 to 0.028:1.

23. A method of deterring abuse of a hydrocodone formulation comprising preparing a pharmaceutical formulation of claims 1-20.
24. The use of hydrocodone or a pharmaceutically acceptable salt thereof, in the preparation of a dosage form according to any of claims 1-20.
25. The use of naltrexone or a pharmaceutically acceptable salt thereof, in the preparation of a dosage form according to any of claims 1-20.
26. The use of hydrocodone or a pharmaceutically acceptable salt thereof; and naltrexone or a pharmaceutically acceptable salt thereof, in the preparation of a dosage form according to any of claims 1-20.